ArticleCancers2022

Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer.

Lei Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.